Scarica l'app Stockscreener
2.05
4.21%
-0.09
Dopo l'orario di chiusura:
2.05
Precedente Chiudi:
$2.14
Aprire:
$2.13
Volume 24 ore:
206.40K
Relative Volume:
0.49
Capitalizzazione di mercato:
$191.75M
Reddito:
-
Utile/perdita netta:
$1.60M
Rapporto P/E:
68.33
EPS:
0.03
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
+14.53%
1M Prestazione:
+28.93%
6M Prestazione:
+43.36%
1 anno Prestazione:
+13.26%
Intervallo 1D:
$2.005
$2.135
Intervallo di 1 settimana:
$1.74
$2.31
Portata 52W:
$1.13
$2.38
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.05 | 200.17M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-13 | Iniziato | Oppenheimer | Outperform |
| 2022-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-26 | Ripresa | JMP Securities | Mkt Outperform |
| 2020-05-13 | Iniziato | Stifel | Buy |
| 2020-05-07 | Iniziato | SVB Leerink | Outperform |
| 2020-04-22 | Iniziato | ROTH Capital | Buy |
| 2020-03-24 | Iniziato | SunTrust | Buy |
| 2020-01-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-03-29 | Iniziato | Oppenheimer | Outperform |
| 2016-02-01 | Ripresa | Oppenheimer | Outperform |
| 2015-10-15 | Iniziato | FBR Capital | Outperform |
| 2015-04-23 | Ripresa | Jefferies | Buy |
| 2015-04-21 | Iniziato | Oppenheimer | Outperform |
| 2014-02-07 | Iniziato | MLV & Co | Buy |
| 2009-12-28 | Reiterato | Cantor Fitzgerald | Buy |
| 2009-07-29 | Iniziato | Cantor Fitzgerald | Buy |
Mostra tutto
Compugen Ltd Borsa (CGEN) Ultime notizie
BillionToOne Stock at $89: Why a New $19.1 Million Position Could Matter Now - AOL.com
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - AOL.com
Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings - AOL.com
Cumberland (CPIX) Q4 2025 Earnings Call Transcript - AOL.com
Compugen (CGEN) Quarterly Loss Near US$7 Million Tests Bullish Profitability Narrative - simplywall.st
Compugen (CGEN) Q4 2025 Earnings Call Transcript - The Globe and Mail
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Compugen earnings beat by $0.68, revenue topped estimates - Investing.com South Africa
Chegg Earnings: Big Quarter Sends Shares Higher - AOL.com
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement (CGEN) - Seeking Alpha
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Compugen Q4 2025 Earnings Call Transcript - MarketBeat
Compugen Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
What Smart Money Loves About Lilly - AOL.com
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Earnings call transcript: Compugen Q4 2025 sees earnings beat, stock surges - Investing.com Nigeria
CGEN: 2025 saw a cash runway extension, profitability, and global clinical trial progress - TradingView
Compugen Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
CGEN: 2025 saw strong revenue growth, a return to profitability, and extended cash runway into 2029 - TradingView
Compugen: Overview of Fourth Quarter Financial Results - Bitget
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Compugen Extends Cash Runway to 2029 and Swings to Profit on AstraZeneca Deal and Clinical Progress - TipRanks
Partnership payments lift Compugen (NASDAQ: CGEN) to 2025 profit - Stock Titan
COMPUGEN ($CGEN) Releases Q4 2025 Earnings - Quiver Quantitative
Compugen stock jumps 5% on fourth quarter earnings beat - Investing.com
Compugen: Q4 Earnings Snapshot - marketscreener.com
Compugen : Corporate Presentation - marketscreener.com
Earnings Breakdown: Compugen Q4 - Benzinga
CGEN: Profitability achieved in 2025, driven by AstraZeneca deal and robust clinical progress - TradingView
Compugen (Nasdaq: CGEN) swings to 2025 profit, extends cash runway to 2029 - Stock Titan
Compugen Reports Fourth Quarter and Full Year 2025 Results - Yahoo Finance
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Uncovering Potential: Compugen's Earnings Preview - Benzinga
Compugen Ltd expected to post earnings of 5 cents a shareEarnings Preview - TradingView
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition - AOL.com
Compugen Ltd (CGEN) Q4 2025: Everything You Need To Know Ahead O - GuruFocus
MSN Money - MSN
Compugen CEO Highlights COM701 Ovarian Cancer MAIA Trial, AstraZeneca and Gilead Updates at Oppenheimer Conf - Defense World
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% - AOL.com
Compugen at Oppenheimer Conference: Strategic Insights on Partnerships - Investing.com India
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
Here's Why Grail Stock Bounced Back 16% Today - AOL.com
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Is Compass Stock a Buy After Kanen Added 1.6 Million Shares to Its Position? - AOL.com
Analyzing Sana Biotechnology (NASDAQ:SANA) & Compugen (NASDAQ:CGEN) - Defense World
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 - AOL.com
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
Compugen Ltd Azioni (CGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):